Cell-extrinsic hematopoietic impact of Ezh2 inactivation in fetal liver endothelial cells.
Neo WH. et al, (2018), Blood, 131, 2223 - 2234
BCR-ABL1 kinase domain mutation screening using next generation sequencing in CML and Ph plus ALL patients
Kizilors A. et al, (2018), BRITISH JOURNAL OF HAEMATOLOGY, 181, 45 - 45
Feasibility of recruitment of patients with Myeloproliferative Neoplasms into the TAP funded TAMARIN study
Harrison C. et al, (2018), BRITISH JOURNAL OF HAEMATOLOGY, 181, 187 - 187
Ruxolitinib induces changes in histone modification status in patients entered into the MAJIC clinical trial
McPherson S. et al, (2018), BRITISH JOURNAL OF HAEMATOLOGY, 181, 47 - 48
The transformative journey of chronic myeloid leukemia.
Neelakantan P. and Mead A., (2018), Int J Hematol Oncol, 7
Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors.
Booth CAG. et al, (2018), Cancer cell, 33, 274 - 291.e8
BONE MARROW MYELOPOIESIS INDEPENDENTLY OF CANONICAL NOTCH SIGNALING
Duarte S. et al, (2018), HAEMATOLOGICA, 102, 456 - 456
Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data
Farmery JHR. et al, (2018), Scientific Reports, 8
Canonical Notch signaling is dispensible for adult steady-state and stress myelo-erythropoiesis.
Duarte S. et al, (2018), Blood
A Single-Cell Approach to Unraveling Abnormal Megakaryocyte Differentiation and Function in Myelofibrosis
Psaila B. et al, (2017), BLOOD, 130
Cell-Intrinsic Depletion of AML1-ETO-Positive Pre-Leukemic HSCs By Kras Activating Mutation
Di Genua C. et al, (2017), BLOOD, 130
Molecular and Functional Characterization of Disease-Propagating Stem Cells in Juvenile Myelomonocytic Leukemia
Louka E. et al, (2017), BLOOD, 130
Unravelling Cell Cycle and Ontogeny Transcriptional Heterogeneity in Hematopoietic Stem Cells through Integrated Single Cell RNA-Seq
Povinelli B. et al, (2017), BLOOD, 130
Tasigna (nilotinib) in chronic myeloid leukemia treatment-free remission after nearly 2 years: an interview with Adam Mead
Mead A., (2017), FUTURE ONCOLOGY, 13, 2401 - 2404
Mbd3/NuRD controls lymphoid cell fate and inhibits tumorigenesis by repressing a B cell transcriptional program.
Loughran SJ. et al, (2017), The Journal of Experimental Medicine, 214, 3085 - 3104
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
Harrison CN. et al, (2017), Blood, 130, 1889 - 1897
Single cell analysis of normal and leukemic hematopoiesis.
Povinelli BJ. et al, (2017), Molecular aspects of medicine
Equivalence of BCSH and WHO diagnostic criteria for ET.
Harrison CN. et al, (2017), Leukemia, 31, 1660 - 1660